Novacyt (NYSE-ALTERNEXT: ALNOV), is a leading diagnostics manufacturer that develops and markets innovative solutions in liquid-based cytology for the detection of cancer, including cervical cancer and other non-gynaecological cancers, and Lab21 is a UK-based global specialist in personalized medicine and clinical diagnostics.

The combined group will create an emerging diagnostics leader with a portfolio of cancer and infectious diseases diagnostic products and services.

Dyens & Co was the exclusive financial advisor of Novacyt’s shareholders on their M&A strategy, and ultimately the stock-for-stock transaction with Lab21.